MarketCap
Autolus Therapeutics plc AUTL
$ 1.24
-5.34%
Facebook
X
Telegram
Autolus Therapeutics plc Long-Term Debt | AUTL
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Autolus Therapeutics plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.8 M | 49.6 M | 47.9 M | 19.2 M | 16.5 M | - | - | 285 K | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 66.8 M | 285 K | 33.4 M |
Quarterly Long-Term Debt Autolus Therapeutics plc
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77 M | 77.7 M | 76.9 M | 66.8 M | 61 M | 61.3 M | 54.7 M | 49.6 M | 48.7 M | 45.8 M | 46.5 M | 47.9 M | 47 M | - | - | - | - | - | - | 16.5 M | - | - | 19.6 M | 50.6 M | 49.5 M | 24.3 M | 24.1 M | 23.7 M | 24.4 M | 25.5 M | - | 380 K | 380 K | - | - | - | 763 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 77.7 M | 380 K | 40.8 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Galectin Therapeutics
GALT
|
20 K | $ 3.29 | -2.66 % | $ 210 M |  USA |
 |
Corcept Therapeutics Incorporated
CORT
|
5.02 M | $ 74.57 | 1.66 % | $ 7.74 B | USA |
 |
Progenity, Inc.
PROG
|
162 M | - | -3.47 % | $ 164 M | USA |
 |
Strongbridge Biopharma plc
SBBP
|
17.1 M | - | 1.52 % | $ 136 M | USA |
 |
Innate Pharma S.A.
IPHA
|
16.9 M | $ 1.59 | 3.25 % | $ 142 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
3.39 M | - | -1.19 % | $ 28.7 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
436 K | $ 58.33 | 2.1 % | $ 11.2 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
5 K | $ 0.88 | -29.93 % | $ 4.82 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
54.8 M | $ 11.61 | 3.46 % | $ 248 K | USA |
 |
Milestone Pharmaceuticals
MIST
|
57.2 M | $ 0.68 | 2.4 % | $ 72.2 M |  Canada |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
6.51 M | $ 95.42 | 0.42 % | $ 7.08 B | USA |
 |
Lipocine
LPCN
|
1.67 M | $ 1.59 | -0.31 % | $ 8.66 M | USA |
 |
PTC Therapeutics
PTCT
|
3 M | $ 64.91 | 1.2 % | $ 5.16 B | USA |
 |
Seres Therapeutics
MCRB
|
72.6 M | $ 1.51 | -3.21 % | $ 13.4 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
340 M | $ 432.77 | 0.04 % | $ 9.71 B | USA |
 |
CEL-SCI Corporation
CVM
|
5.68 M | $ 1.31 | -7.09 % | $ 10.5 M | USA |
 |
Inventiva S.A.
IVA
|
10 M | $ 4.01 | 1.65 % | $ 240 M | France |
 |
MeiraGTx Holdings plc
MGTX
|
109 K | $ 9.68 | 0.57 % | $ 779 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
487 | $ 1.85 | -1.07 % | $ 2.42 M | USA |
 |
Eton Pharmaceuticals
ETON
|
21.8 M | $ 68.4 | 1.27 % | $ 1.84 B | USA |
 |
IDEAYA Biosciences
IDYA
|
27.6 M | $ 32.71 | 3.02 % | $ 2.89 B | USA |
 |
Protalix BioTherapeutics
PLX
|
6.94 M | $ 3.13 | 9.44 % | $ 246 M |  Israel |
 |
Lantern Pharma
LTRN
|
52.8 K | $ 0.47 | 1.53 % | $ 5.12 M | USA |
 |
Foghorn Therapeutics
FHTX
|
40.3 M | $ 2.04 | 7.37 % | $ 128 M | USA |
 |
Ocugen
OCGN
|
27.5 M | $ 0.96 | 0.8 % | $ 300 M | USA |
 |
Oncolytics Biotech
ONCY
|
787 K | $ 0.42 | 9.19 % | $ 40.3 M | Canada |
 |
Minerva Neurosciences
NERV
|
111 K | $ 2.56 | 2.81 % | $ 21.7 M | USA |
 |
Kamada Ltd.
KMDA
|
9.44 M | $ 8.1 | 0.43 % | $ 467 M | Israel |
 |
Neurocrine Biosciences
NBIX
|
415 M | $ 173.86 | 2.79 % | $ 17.3 B | USA |
 |
Nanobiotix S.A.
NBTX
|
39.1 M | $ 32.73 | 0.03 % | $ 1.57 T | France |
 |
Mereo BioPharma Group plc
MREO
|
1.22 M | $ 0.31 | 2.89 % | $ 247 M |  Britain |
 |
Maravai LifeSciences Holdings
MRVI
|
286 M | $ 7.71 | -1.91 % | $ 1.11 B | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
49.4 M | $ 1.86 | 1.34 % | $ 675 M | USA |
 |
Moleculin Biotech
MBRX
|
222 K | $ 8.05 | -0.12 % | $ 9.54 M | USA |
 |
Nurix Therapeutics
NRIX
|
52.9 M | $ 16.46 | 3.65 % | $ 1.43 B | USA |
 |
Nkarta
NKTX
|
69.5 M | $ 1.49 | 10.0 % | $ 110 M | USA |
 |
MacroGenics
MGNX
|
31.6 M | $ 2.33 | -3.85 % | $ 147 M | USA |
 |
Protagonist Therapeutics
PTGX
|
8.04 M | $ 134.78 | -1.06 % | $ 8.57 B | USA |
|
Nuvation Bio
NUVB
|
47.2 M | $ 4.3 | 2.26 % | $ 1.47 B | USA |
 |
Novo Nordisk A/S
NVO
|
7.24 B | $ 41.06 | 0.88 % | $ 182 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
7.04 M | $ 0.95 | 0.07 % | $ 14.5 M | USA |
 |
NextCure
NXTC
|
3.6 M | $ 6.3 | 5.35 % | $ 33.5 M | USA |
 |
Rocket Pharmaceuticals
RCKT
|
19.4 M | $ 2.47 | 0.82 % | $ 274 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
435 K | $ 1.25 | 2.87 % | $ 65.7 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
69 K | $ 8.16 | 12.24 % | $ 710 M | USA |
 |
Kymera Therapeutics
KYMR
|
1.46 M | $ 135.02 | -1.19 % | $ 11.4 B | USA |
 |
Oragenics
OGEN
|
152 K | $ 0.35 | 1.4 % | $ 755 K | USA |
 |
Ovid Therapeutics
OVID
|
12 M | $ 2.77 | -1.07 % | $ 361 M | USA |
 |
Passage Bio
PASG
|
4.61 M | $ 3.91 | 3.44 % | $ 12.5 M | USA |